Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors

Andrew J. Sawyer, Jennifer K. Saucier-Sawyer, Carmen J. Booth, Jie Liu, Toral Patel, Joseph M. Piepmeier, W. Mark Saltzman

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Direct delivery of chemotherapy agents to the brain via degradable polymer delivery systems-such as Gliadel®-is a clinically proven method for treatment of glioblastoma multiforme, but there are important limitations with the current technology-including the requirement for surgery, profound local tissue toxicity, and limitations in diffusional penetration of agents-that limit its application and effectiveness. Here, we demonstrate another technique for direct, controlled delivery of chemotherapy to the brain that provides therapeutic benefit with fewer limitations. In our new approach, camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles are infused via convection-enhanced delivery (CED) to a stereotactically defined location in the brain, allowing simultaneous control of location, spread, and duration of drug release. To test this approach, CPT-PLGA nanoparticles (~100 nm in diameter) were synthesized with 25% drug loading. When these nanoparticles were incubated in culture with 9L gliosarcoma cells, the IC50 of CPT-PLGA nanoparticles was 0. 04 μM, compared to 0. 3 μM for CPT alone. CPT-PLGA nanoparticles stereotactically delivered by CED improved survival in rats with intracranial 9L tumors: the median survival for rats treated with CPT-PLGA nanoparticles (22 days) was significantly longer than unloaded nanoparticles (15 days) and free CPT infusion (17 days). CPT-PLGA nanoparticle treatment also produced significantly more long-term survivors (30% of animals were free of disease at 60 days) than any other treatment. CPT was present in tissues harvested up to 53 days post-infusion, indicating prolonged residence at the local site of administration. These are the first results to demonstrate the effectiveness of combining polymer-controlled release nanoparticles with CED in treating fatal intracranial tumors.

Original languageEnglish (US)
Pages (from-to)34-42
Number of pages9
JournalDrug Delivery and Translational Research
Volume1
Issue number1
DOIs
StatePublished - Feb 2011

Fingerprint

Camptothecin
Convection
Nanoparticles
Polymers
Neoplasms
Therapeutics
Brain
Gliosarcoma
Drug Therapy
Survival
Glioblastoma
Inhibitory Concentration 50
Survivors
polylactic acid-polyglycolic acid copolymer
Technology

Keywords

  • Camptothecin
  • Controlled release
  • Drug delivery
  • Glioma
  • Polymer nanoparticles

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. / Sawyer, Andrew J.; Saucier-Sawyer, Jennifer K.; Booth, Carmen J.; Liu, Jie; Patel, Toral; Piepmeier, Joseph M.; Saltzman, W. Mark.

In: Drug Delivery and Translational Research, Vol. 1, No. 1, 02.2011, p. 34-42.

Research output: Contribution to journalArticle

Sawyer, Andrew J. ; Saucier-Sawyer, Jennifer K. ; Booth, Carmen J. ; Liu, Jie ; Patel, Toral ; Piepmeier, Joseph M. ; Saltzman, W. Mark. / Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. In: Drug Delivery and Translational Research. 2011 ; Vol. 1, No. 1. pp. 34-42.
@article{f3e94dddac6843608c13ad7c4f02e3f1,
title = "Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors",
abstract = "Direct delivery of chemotherapy agents to the brain via degradable polymer delivery systems-such as Gliadel{\circledR}-is a clinically proven method for treatment of glioblastoma multiforme, but there are important limitations with the current technology-including the requirement for surgery, profound local tissue toxicity, and limitations in diffusional penetration of agents-that limit its application and effectiveness. Here, we demonstrate another technique for direct, controlled delivery of chemotherapy to the brain that provides therapeutic benefit with fewer limitations. In our new approach, camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles are infused via convection-enhanced delivery (CED) to a stereotactically defined location in the brain, allowing simultaneous control of location, spread, and duration of drug release. To test this approach, CPT-PLGA nanoparticles (~100 nm in diameter) were synthesized with 25{\%} drug loading. When these nanoparticles were incubated in culture with 9L gliosarcoma cells, the IC50 of CPT-PLGA nanoparticles was 0. 04 μM, compared to 0. 3 μM for CPT alone. CPT-PLGA nanoparticles stereotactically delivered by CED improved survival in rats with intracranial 9L tumors: the median survival for rats treated with CPT-PLGA nanoparticles (22 days) was significantly longer than unloaded nanoparticles (15 days) and free CPT infusion (17 days). CPT-PLGA nanoparticle treatment also produced significantly more long-term survivors (30{\%} of animals were free of disease at 60 days) than any other treatment. CPT was present in tissues harvested up to 53 days post-infusion, indicating prolonged residence at the local site of administration. These are the first results to demonstrate the effectiveness of combining polymer-controlled release nanoparticles with CED in treating fatal intracranial tumors.",
keywords = "Camptothecin, Controlled release, Drug delivery, Glioma, Polymer nanoparticles",
author = "Sawyer, {Andrew J.} and Saucier-Sawyer, {Jennifer K.} and Booth, {Carmen J.} and Jie Liu and Toral Patel and Piepmeier, {Joseph M.} and Saltzman, {W. Mark}",
year = "2011",
month = "2",
doi = "10.1007/s13346-010-0001-3",
language = "English (US)",
volume = "1",
pages = "34--42",
journal = "Drug Delivery and Translational Research",
issn = "2190-393X",
publisher = "Springer Publishing Company",
number = "1",

}

TY - JOUR

T1 - Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors

AU - Sawyer, Andrew J.

AU - Saucier-Sawyer, Jennifer K.

AU - Booth, Carmen J.

AU - Liu, Jie

AU - Patel, Toral

AU - Piepmeier, Joseph M.

AU - Saltzman, W. Mark

PY - 2011/2

Y1 - 2011/2

N2 - Direct delivery of chemotherapy agents to the brain via degradable polymer delivery systems-such as Gliadel®-is a clinically proven method for treatment of glioblastoma multiforme, but there are important limitations with the current technology-including the requirement for surgery, profound local tissue toxicity, and limitations in diffusional penetration of agents-that limit its application and effectiveness. Here, we demonstrate another technique for direct, controlled delivery of chemotherapy to the brain that provides therapeutic benefit with fewer limitations. In our new approach, camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles are infused via convection-enhanced delivery (CED) to a stereotactically defined location in the brain, allowing simultaneous control of location, spread, and duration of drug release. To test this approach, CPT-PLGA nanoparticles (~100 nm in diameter) were synthesized with 25% drug loading. When these nanoparticles were incubated in culture with 9L gliosarcoma cells, the IC50 of CPT-PLGA nanoparticles was 0. 04 μM, compared to 0. 3 μM for CPT alone. CPT-PLGA nanoparticles stereotactically delivered by CED improved survival in rats with intracranial 9L tumors: the median survival for rats treated with CPT-PLGA nanoparticles (22 days) was significantly longer than unloaded nanoparticles (15 days) and free CPT infusion (17 days). CPT-PLGA nanoparticle treatment also produced significantly more long-term survivors (30% of animals were free of disease at 60 days) than any other treatment. CPT was present in tissues harvested up to 53 days post-infusion, indicating prolonged residence at the local site of administration. These are the first results to demonstrate the effectiveness of combining polymer-controlled release nanoparticles with CED in treating fatal intracranial tumors.

AB - Direct delivery of chemotherapy agents to the brain via degradable polymer delivery systems-such as Gliadel®-is a clinically proven method for treatment of glioblastoma multiforme, but there are important limitations with the current technology-including the requirement for surgery, profound local tissue toxicity, and limitations in diffusional penetration of agents-that limit its application and effectiveness. Here, we demonstrate another technique for direct, controlled delivery of chemotherapy to the brain that provides therapeutic benefit with fewer limitations. In our new approach, camptothecin (CPT)-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles are infused via convection-enhanced delivery (CED) to a stereotactically defined location in the brain, allowing simultaneous control of location, spread, and duration of drug release. To test this approach, CPT-PLGA nanoparticles (~100 nm in diameter) were synthesized with 25% drug loading. When these nanoparticles were incubated in culture with 9L gliosarcoma cells, the IC50 of CPT-PLGA nanoparticles was 0. 04 μM, compared to 0. 3 μM for CPT alone. CPT-PLGA nanoparticles stereotactically delivered by CED improved survival in rats with intracranial 9L tumors: the median survival for rats treated with CPT-PLGA nanoparticles (22 days) was significantly longer than unloaded nanoparticles (15 days) and free CPT infusion (17 days). CPT-PLGA nanoparticle treatment also produced significantly more long-term survivors (30% of animals were free of disease at 60 days) than any other treatment. CPT was present in tissues harvested up to 53 days post-infusion, indicating prolonged residence at the local site of administration. These are the first results to demonstrate the effectiveness of combining polymer-controlled release nanoparticles with CED in treating fatal intracranial tumors.

KW - Camptothecin

KW - Controlled release

KW - Drug delivery

KW - Glioma

KW - Polymer nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=81155150555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81155150555&partnerID=8YFLogxK

U2 - 10.1007/s13346-010-0001-3

DO - 10.1007/s13346-010-0001-3

M3 - Article

VL - 1

SP - 34

EP - 42

JO - Drug Delivery and Translational Research

JF - Drug Delivery and Translational Research

SN - 2190-393X

IS - 1

ER -